Particle.news
Drug Development Weight Loss Drugs HIV Prevention Cancer Treatment Semaglutide Candidates GLP-1s Competition Phase 3 Ketamine Weight-Loss Drugs Drug Safety Oncology Treatments Efficacy Studies Mpox Treatment Puberty Blockers Mental Health Diabetes Treatment Neurological Conditions Drug Approval Drug Supply ALS Phase 2 Regulatory Approval Response Rate Drug Effectiveness Phase 3 Trials
The acquisition solidifies BMS's control over Abecma, a CAR T-cell therapy for multiple myeloma, as 2seventy Bio concludes its turbulent independent run.
